What is it used for?
Tasfygo contains tasurgratinib, an FGFR inhibitor. The Japanese review covers unresectable biliary tract cancer with an FGFR2 fusion that has progressed after chemotherapy. The FGFR2 finding and previous treatment must be documented; this is not a medicine for every biliary cancer.Tasfygo contains tasurgratinib, an FGFR inhibitor. The Japanese review covers unresectable biliary tract cancer with an FGFR2 fusion that has progressed after chemotherapy. The FGFR2 finding and previous treatment must be documented; this is not a medicine for every biliary cancer.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- tasurgratinibtasurgratinib
- Form and strength
- Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.
- Manufacturer / applicant
- Eisai Co., Ltd.Eisai Co., Ltd.
Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.
Safety and clinical review
The review highlights increased blood phosphate, retinal disorders, nail problems and hand-foot skin reactions.The review highlights increased blood phosphate, retinal disorders, nail problems and hand-foot skin reactions.
- Phosphate monitoringPhosphate monitoring
- Eye symptoms and retinal assessmentEye symptoms and retinal assessment
- Nail and skin reactionsNail and skin reactions
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is TASFYGO used for?
Tasfygo contains tasurgratinib, an FGFR inhibitor. The Japanese review covers unresectable biliary tract cancer with an FGFR2 fusion that has progressed after chemotherapy. The FGFR2 finding and previous treatment must be documented; this is not a medicine for every biliary cancer.Tasfygo contains tasurgratinib, an FGFR inhibitor. The Japanese review covers unresectable biliary tract cancer with an FGFR2 fusion that has progressed after chemotherapy. The FGFR2 finding and previous treatment must be documented; this is not a medicine for every biliary cancer.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of TASFYGO should I ask about?
Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.Oral tablets containing 35 mg tasurgratinib, supplied as the succinate salt.
Read the primary sourceWhat determines the price of TASFYGO?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using TASFYGO?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.